Myriad Genetics Inc
$3.89
-$0.25 (-6.04%)
$3.86Day Range$4.17
Key Statistics
Market Cap
$395.99M
Shares Outstanding
95.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 6, 1995
Round Lot
100
Locale
US
Trading Data
Day Open
$4.15
Day High
$4.17
Day Low
$3.86
Volume
3.51M
VWAP
$3.95
Prev Close
$4.14
Transactions
--
Acc. Volume
--
About Myriad Genetics Inc
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESSIC 28352,700 employees322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116801-584-3600IPO Oct 6, 1995US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000899923
- Composite FIGI
- BBG000D9H9F1
- Share Class FIGI
- BBG001S86FS9
- Ticker Root
- MYGN
- SIC Code
- 2835
About Myriad Genetics Inc (MYGN) Stock
Myriad Genetics Inc (MYGN) closed the 2026-09-18 session at $3.89, down 6.04% versus the previous close (-0.25). The stock opened at $4.15 and traded between $3.86 and $4.17 during that session. Session trading volume was 3.5M shares. The volume-weighted average price (VWAP) is $3.95.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Myriad Genetics Inc has a market capitalization of $396.0 million. The company operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry classification. MYGN is listed on the XNAS exchange. The company employs approximately 2,700 people. Myriad Genetics Inc is headquartered in SALT LAKE CITY, UT. The recorded listing date is 1995-10-06.
On this page you can find market MYGN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector.